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Abstract 
 
Colorectal-cancer (CRC) is the third most common cause of cancer-related-death, and hence 
there is a need for the identification of novel-agents to improve the efficacy of existing-therapies. 
There is growing evidence for the anti-tumor-activity of crocin, although its activity and 
molecular-mechanisms in CRC remains to be elucidated. Here we explored the therapeutic-
application of crocin or its combination with 5-Flurouracil in a mouse-model of colitis-associated 
colon-cancer. The anti-proliferative-activity of crocin was assessed in 2- and 3-dimensional cell-
culture-models. The migratory-behaviors were determined, while the expression-levels of 
several-genes were assessed by qRT-PCR/Western-blotting. We examined the anti-
inflammatory properties of crocin by pathological-evaluation and disease-activity-index as well 
as oxidative/ antioxidant markers: malondialdehyde (MDA) and total-thiols (T-SH) levels and  
superoxide-dismutase (SOD) and catalase (CAT) activity. Crocin suppressed cell-growth and 
the invasive-behavior of CRC-cells through modulation of the Wnt-pathway and E-cadherin. 
Moreover, administration of crocin alone, or in combination with 5-FU dramatically reduced the 
tumor-number and tumor-size in both distal/mid-colon followed by reduction in disease-activity-
index. Crocin also suppressed the colonic-inflammation induced by Dextran-sulfate-sodium and 
notably recovered the increased-levels of MDA, decreased Thiol-levels and activity of CAT-
levels. Crocin was able to ameliorate the severe-inflammation with mucosal-ulcers and high 
grade-dysplastic-crypts as detected by inflammation-score, Crypt-loss, pathological-changes 
and histology-scores. We demonstrated an antitumor-activity of crocin in CRC and its potential 
role in improvement of inflammation with mucosal ulcers and high grade dysplastic crypts, 
supporting the desireability of further investigations on the therapeutic potential of this approach 
in CRC. 
 
Keywords: colorectal cancer; crocin; anti-tumor effect; colitis-associated colorectal cancer 
gastrointestinal 
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Introduction 
Colorectal cancer (CRC) remains the third most common type of malignancy globally (Siegel, 
Miller & Jemal, 2016). Recently, both clinical and basic science studies have made considerable 
progress in the therapeutic strategies used in CRC; these currently include surgery, 
radiotherapy and, most notably chemotherapy. However, the overall survival rate of patients 
with CRC remains disappointing due to: drug-resistance, severe side effects and high 
recurrence rate (Longley, Allen & Johnston, 2006). 5-fluorouracil (5-FU) treatment, alone or in 
combination with other chemical cytotoxic drugs, is among the routinely used standard therapies 
in CRC (Bahrami et al., 2017b; Bahrami et al., 2017c; Bahrami et al., 2017d; Hammond, Swaika 
& Mody, 2016). Despite its therapeutic benefits, 5-FU has also shown limited efficacy, high 
resistance, and a low response rate in advanced CRC patients (Bahrami et al., 2017a; Zhang, 
Yin, Xu & Chen, 2008). These limitations have necessitated further research for developing 
more efficient alternative or potential combinational agents in chemopreventive and 
chemotherapeutic strategies in order to enhance effectiveness, while reducing toxicity and 
resistance. 
Recently, crocin has emerged as a novel anti-cancer agent in the treatment of several tumor 
types, including hepatic, pancreatic, prostate, breast, and colorectal cancers (Amin et al., 2016; 
Aung et al., 2007; Chryssanthi, Dedes, Karamanos, Cordopatis & Lamari, 2011; D'Alessandro 
et al., 2013; Dhar et al., 2009). There are already studies showing the therapeutic value of 
crocin as anti-convulsant, anti-inflammatory, anti-depressant and anti-tumor molecule 
(Hosseinzadeh, 2014). Hoshyar et al. showed that crocin could induce apoptosis in gastric 
adenocarcinoma cells via increasing Bax/Bcl-2 ratio in stimulated cells (Hoshyar, Bathaie & 
Sadeghizadeh, 2013). Bathaie et al. explored the beneficial activity of saffron extract on gastric 
cancer in an in vivo experiment. They showed that an aqueous extract of saffron, inhibited the 
progression of cancer in rats dose dependently in gastric cancer (Bathaie, Hoshyar, Miri & 
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Sadeghizadeh, 2013; Bathaie, Miri, Mohagheghi, Mokhtari-Dizaji, Shahbazfar & Hasanzadeh, 
2013). Moreover, a study in diethylnitrosamine-treated rats showed that saffron potently 
inhibited nodular and foci of altered hepatocyte formation  in the rat liver. The authors found that 
this inhibition was correlated with induced apoptosis, decreased cell proliferation, reduced 
oxidative stress and down-regulation of some inﬂammatory markers including NF-κB (nuclear 
factor kappa-light-chain-enhancer of activated B cells), Inducible nitric oxide synthase (iNOS) 
and COX-2 (Amin, Hamza, Bajbouj, Ashraf & Daoud, 2011). Furthermore, Aung et al. reported 
that crocus sativus extract and crocin possess remarkable anti-proliferative effects on CRC cells 
(Aung et al., 2007). Similarly, it has been shown that long-term treatment with crocin elevated 
survival rate in rats with CRC (Garcia-Olmo et al., 1999).  
In this current study, we assessed the anti-tumor activity of crocin alone to investigate its 
potential as a chemotherapeutic compound, and also in combination with 5-FU to explore 
whether crocin treatment could improve the anti–tumor activity of 5-FU both in in vitro and in 
colon cancer mice models. Moreover, we investigated the anti-oxidant activity of crocin. Next, to 
investigate the underlying molecular changes within anti-cancer activity of crocin, alone and in 
combination with 5-FU, we evaluated the expression of related specific key molecular markers 
in monolayer and three-dimensional cultured cells to imitate the tumor microenvironment. 
 
Methods and materials: 
Drugs and chemicals: 
Crocin was obtained from Faculty of Pharmacy, Mashhad University of Medical 
Sciences (Mashhad, Iran). 5-FU was purchased from MUMS and dissolved in ethanol or sterile 
water. Dulbecco’s Modified Eagle Medium (DMEM), fetal bovine serum (FBS), penicillin (50 
IU/ml) and streptomycin (50 µg/ml) were purchased from Gibco (Gaithersburg, MD). 
Azoxymethane (AOM), and dextran sodium sulfate (DSS; MW=40 kD) were purchased from 
Sigma Chemical Co. (St. Louis, MO, USA).  
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Cell culture: 
CT-26 cell line was originally purchased from Pasteur institute, Tehran, Iran. The cells were 
grown in DMEM containing 10% heat-inactivated FBS and 1% streptomycin/penicillin. The cells 
were maintained at 37 °C in 5% CO2 atmosphere. Regular passaging was performed in their 
exponentially growing phase, at 70%–80% confluency, by using trypsin-EDTA (Rovithi et al., 
2017). 
 
Growth inhibition studies: 
The cell growth inhibitory effects of crocin, 5-FU, and their combination were evaluated by the 
MTT assay before and after 24-72 hour-treatment. CT-26 cells were treated for 24 hours with 
crocin (1-500 μM), 5-FU (1-500 nM), and simultaneous combination at a fixed ratio based on 
IC50 (i.e. concentration of a drug required for 50% inhibition of cell growth) of each drug. The 
plates were then processed for MTT as described previously (Avan et al., 2013b). 
 
Evaluation of synergistic/antagonistic interaction with 5-FU: 
The pharmacological interaction between crocin and 5-FU was evaluated by the median drug 
effect analysis method as described previously (Maftouh et al., 2014b). Briefly, the combination 
index (CI) was calculated to compare cell growth inhibition of the combination and each drug 
alone. Data analysis was carried out using CalcuSyn software (Biosoft, Oxford, UK). 
 
Multicellular spheroids: 
The spheroids were formed by seeding 105 cells per ml in DMEM/F12+GlutaMAX-I (1:1) in 
agarose coated 96-well plates. The cell attachment, growth and cytotoxic effects were 
determined for 10 days under the inverted phase contrast microscope Leica-DMI300B (Leica, 
Wetzlar, Germany). Spheroid volume (V) was defined from the geometric mean of the 
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perpendicular diameters D= (Dmax+Dmin)/2, as follows: V= (4/3) ×π (D/2)3 (Maftouh et al., 
2014c). 
 
In vitro invasion assay: 
Cell invasion assays were carried out using trans-well chambers with polycarbonate 
membranes and 8-µm pores (Maftouh et al., 2014b; Nedaeinia et al., 2016). The trans-well 
filters were coated with 100 µl of 0.1 mg/mL collagen I solution. Briefly, 105 cells were plated on 
the upper face of the filter and incubated with crocin at 2 mM in serum free media. Migratory 
cells attached to the polycarbonate membranes were fixed with paraformaldehyde solution for 
24 hours. The filters were then photographed and counted after visualization with Giemsa stain. 
 
Migration assays  
The ability of crocin and its combination with 5-FU to inhibit the migratory behavior of CT-26 
cells was investigated by in vitro migration assay, as described previously (Giovannetti et al., 
2014). The cells were exposed to the drug at their 2 mM. Images were taken at the beginning of 
the exposure (time 2), with those taken after 7,11, 13, 23, 32 hours. 
 
Quantitative Reverse-Transcriptase Polymerase-Chain-Reaction (qRT-PCR): 
Total RNAs were extracted from the cells before and after treatment with crocin at IC50 (3mM) 
and using the RNXPLOS (CinaColon, Tehran, Iran), according to the manufacturer’s protocol. 
cDNA was synthesized by cDNA Synthesis Kit (CinaColon, Tehran, Iran). Quantitative RT-PCR 
was performed with specific primers for CyclinD1, survivin, MMP-2, MMP-9, and E-cadherin 
(Macrogene co, Seoul, Korea). The cDNA was amplified by ABI-PRISM StepOne instrument 
(Applied Biosystems, Foster City, CA). Gene expression data were normalized to GAPDH, 
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using a standard curve of cDNAs purchased from Quantitative PCR Human Reference RNA 
(Stratagene, La Jolla, CA), as described (Maftouh et al., 2014a)(Peters et al., 2014). 
 
Cell cycle assay 
To further investigate the anti-proliferative effect of crocin on cell cycle progression, CT-26 cells 
were treated with two concentrations of crocin ( 3mM, 5mM ) for 24 hours and were analyzed 
using flow cytometry, as described  previously (Giovannetti et al., 2014)(Marjaneh et al., 2018). 
The effect of drugs on modulation of cell cycle was assessed in the cells treated for 24 hours with 
two concentrations of crocin at IC50 concentrations. Cells were stained by propidium iodide (PI) 
and cell cycle modulation was determined using a FACSCalibur flow cytometer (Becton 
Dickinson, San José, CA), equipped with the CELLQuest software for data analysis. The ability 
of crocin and its combination with 5-fu to induce cell death was explored by measuring sub-G1 
regions during cell cycle analysis, as described previously.  
 
Western blot analysis: 
Western blot analyses were performed as described previously (Anto, Mukhopadhyay, Denning 
& Aggarwal, 2002). Briefly, 40 μg of proteins were separated on a 10% SDS-polyacrylamide gel 
and transferred onto PVDF membrane (Immobilion®-FL, Millipore, Billerica, MA). The 
membrane was incubated overnight with rabbit anti-CyclinD1 (Santa Cruz Biotechnology, Santa 
Cruz, CA), anti-PI3K, anti-p-Akt, and anti-p-GSK3α/β (Abcam, Cambridge, UK), and anti-β-actin 
(1:10000; Sigma–Aldrich). The secondary antibody was goat anti-rabbit (1:10000, Westburg, 
Leusden, The Netherlands). The membrane was then proceeded for visualization via 
chemiluminescence detection (Avan et al., 2013a; Avan et al., 2012). 
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Animal experiment: 
The animal experiments were approved by Ethical Committee of animal experiment of the 
Mashhad University of Medical Science. Eightweek old female C57BL/6 mice were supplied by 
Pasteur Institute (Tehran, Iran) and divided into 4 groups (n=6 each): control, treated with 5-FU, 
or crocin, or a 5-FU/crocin combination. Mice were given a single intraperitoneal injection of 
AOM (10 mg/kg body weight followed by three cycles of 1.5% DSS in drinking water for 1 week 
and normal drinking water for 2 weeks (Kawabata, Tung, Shoyama, Sugie, Mori & Tanaka, 
2012). Starting one week after the second DSS exposure, groups 3, 4, and 5 received diets 
containing crocin (200 ppm in drinking water), 5-FU (35 mg/kg once weekly (Almagrami, 
Alshawsh, Saif-Ali, Shwter, Salem & Abdulla, 2014) and crocin + 5-FU, respectively. Group 1 
was served as an untreated control. All animals were sacrificed at week 10. For macroscopic 
and histological examination of tumors, the colons were isolated and washed by ice-cold 
phosphate-buffered saline (PBS) and opened longitudinally and assessed tumor number and 
tumor size with digital caliper. Tumor localization was also determined. Then, distal colon 
samples were placed into 10% formalin solution for histopathological examination. The 
histopathological examination was conducted on paraffin-embedded 5 μm sections which were 
stained with hematoxylin and eosin (H&E). The middle parts of colons were stored at -70°C for 
evaluation of oxidative/ antioxidative markers. For this purpose, colonic tissues were 
homogenized on ice in tissue-lysis buffer. Homogenates were then centrifuged at 4°C for 1 h at 
10000 rpm, and the supernatants were used for oxidative/ antioxidative markers. 
 
Scoring Inflammation 
The inflammation was scored in the large bowel. Large intestinal inflammation was graded with 
respect to the morphological criteria (Sugie, Suzuki, Tanaka & Kohno, 2005) as following: 
normal appearance (grade 0); shortening and loss of the basal 1/3 of the actual crypts together 
with mild inflammation in the mucosa (grade 1); loss of the basal 2/3 of the crypts and moderate 
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inflammation in the mucosa (grade 2); loss of all of the crypts plus severe inflammation in the 
mucosa and sub-mucosa, while the surface epithelium retained (grade 3); the mucosal ulcer 
presentation with sever inflammation in the mucosa, sub-mucosa, muscularis propria, and/or 
subserosa (grade 4). The scoring was carried out on the entire colon with/without proliferative 
lesions and was considered as a mean score/mouse (Hashemzehi et al., 2018).  
 
Measurement of malondialdehyde (MDA) 
MDA level is a marker of lipid peroxidation and was used to evaluate the antioxidant activity of 
crocin. Shortly, 1 ml of 10% homogenates mixed with 2 mL of TBA + TCA + HCL solution for 45 
minutes in a boiling water bath and centrifuged for 10 minutes. Then, the absorbance at 535 nm 
was read and MDA was calculated by C (M) = A ⁄1.65×105) (Hashemzehi et al., 2018).     
 
Measurement of total thiol groups (SH) 
Total thiol was measured using DTNB (Di-Tio nitro benzoic acid) reagent. 1ml of Tris-EDTA 
buffer (pH = 8.6) was added to tissue homogenate. The specimen absorbance read at 412 nm 
against Tris-EDTA buffer alone (A1). Then 20 μl of DTNB reagents were added to this solution 
and stored for 15 minutes at room temperature. Then, the sample absorbance was record again 
(A2). The absorbance of DTNB reagent was record lonely as a blank (B). Total thiol 
concentration (mM) was calculated from the following formula (Total thiol concentration (mM) = 
(A2-A1-B) × 1.07 / 0.05 × 13.6) (Hosseinzadeh & Sadeghnia, 2005). 
Measurement of superoxide dismutase (SOD) and catalase (CAT) activity 
SOD was assessed by Ransod kit (Randox Laboratory, UK), while CAT activity was evaluated 
as described by Aebi et al (Aebi, 1984). The principle of this method was based on the 
hydrolyzation of H2O2 in phosphate buffer, pH 7.0, and essential volume of sample and reducing 
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absorbance at 240 nm. Enzyme response velocity can be measured by the conversion of H2O2 
to H2O and O2 in 1min below standard condition (Hashemzehi et al., 2018). 
 
Statistical analysis: 
All experiments were performed in triplicate and repeated at least twice. Data were expressed 
as mean values ± SEM and analyzed by Student’s t-test or ANOVA followed by Tukey's multiple 
comparison test. Data were analyzed by SPSS v.20 statistical software (IBM, Chicago). 
Statistical significance was set at P<0.05 (Avan et al., 2014)(Oladi et al., 2015; Avan et al., 
2013). 
 
Result 
Crocin inhibits colon cancer cell growth in monolayer cell culture 
To investigate the anti-proliferative activity of crocin alone and its combination with 5-FU, CT26 
cells were exposed to increasing concentrations of crocin (1nM–10mM) and 5-FU (1–50 mg/ml) 
for 24 hr. This analysis showed that crocin and 5-FU inhibited cell growth in a dose-dependent 
manner (Fig. 1A). Results clearly showed that co-treatment of crocin and 5-FU decreased the 
IC50 value of 5-FU. The median drug effect analysis, comparing cell growth inhibition of the 
combination and each drug alone revealed a slight synergism between crocin and 5-FU 
(Fig.1B). 
 
Crocin causes tumor shrinkage in CT-26 cells 
To further assess whether crocin could be active in three-dimensional models of cell culture and 
overcome the major obstacles in conventional cell culture method, CT-26 spheroids were 
developed and treated with crocin at IC50 (3 mM) and 5xIC50 values. Tumor shrinkage was 
detected after 8 days as shown in Figure 1C.  
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Crocin and its combination with 5-FU inhibit invasive behavior of CRC cells  
The effect of crocin on cell invasion was explored by the invasion assay in the cells treated with 
crocin at IC50 (3 mM) and 5xIC50 values. Our data showed that the invasion of CT-26 cells, 
treated with crocin and 5-FU in combination, was significantly reduced as compared with control 
group (Fig. 1D). To further investigate the mechanism of the inhibitory effect of crocin on CRC 
invasive behavior, expression of E-cadherin, a cell adhesion molecule, was analyzed in the 
presence and absence of crocin in these cells. Results showed that crocin significantly 
increased expression of E-cadherin in crocin-stimulated cells (Fig.1E).  
 
Crocin and its combination with 5FU inhibited the migratory behavior of colorectal cancer 
cells  
To investigate the effects of crocin on migratory behavior, a scratch mobility assay was carried 
out in CT26 cells (Fig. 1F). The cells were exposed to crocin in IC50 concentration (3mM) and 
they showed a significant reduction of migration starting after 20 hours exposure to crocin 
compared to control.  
To further confirm the anti-metastatic behavior of the cells treated with crocin, we evaluated the 
expression of matrix metalloprotease-2 and -9 (MMP-2 and MMP-9), two gelatinases which 
facilitate cell invasion by breaking down the extracellular matrix (Said, Raufman & Xie, 2014). 
As shown in figure 1E, crocin significantly suppressed the expression of MMP-2 and MMP-9 
suggesting the mechanism by which crocin decreased cellular migration and metastasis in CRC 
cells. 
 
Crocin suppresses cell cycle progression in CRC cells. 
To further explore the regulatory effect of crocin on cell cycle progression, CT-26 cells were 
treated with two concentrations of crocin (3 mM and 5 mM) for 24 hours and were analyzed by 
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flowcytometry method. Our results indicated that crocin significantly increased the percentage of 
sub G1 population in dose dependent manner (Fig 2 A-D). As shown in Figure 2, when cells 
were treated with crocin (3 mM), the percentage of Sub-G1 population showed a marked 
increase (23.1%) compared with the control group (1.1%). These data suggest that crocin 
induces CRC cell apoptosis by arresting cells in G0/G1 phase of cell cycle. 
 
Crocin suppresses tumor growth in a mouse model of colitis-associated colorectal 
cancer 
We first develop colitis-associated colorectal cancer models, as the workflow outlined in Fig 3A. 
Mice were given 10 mg/kg body weight AOM. One week after AOM injection, they received 
1.5% DSS/oral-gavage for 7 days, followed by 2 weeks rest. One week after DSS exposure 
groups 3, 4, and 5 were treated with crocin, 5-FU, crocin and 5-FU for 15 weeks, respectively.  
The possible physiological significance of anti-proliferative effect of crocin was demonstrated by 
findings that crocin potently decreased CRC growth in animal model too. As shown in Fig.3 B, 
the tumor numbers were significantly reduced in crocin and 5-FU groups. Interestingly this 
reduction was much higher in combination group (Fig.3B). Similar results were also observed 
for tumor size and tumor number based on the location with respect to the colon area and we 
observed treatments had more impact on larger tumor ( more than 2 mm in diameter.(Fig. 3C-
D). Moreover, our data showed that tumor area with respect to the colon length was markedly 
decreased in combination group, compared to crocin or 5-FU groups or control group (Fig. 3E). 
Also crocin was able to improve the colon length, compared to control mice which they didn’t 
received therapy (Fig 3 F-G). 
 
Crocin affects MDA, thiol and CAT activities 
To determine the role of crocin on oxidative stress, the levels of SOD, CAT and MDA and thiol 
were analyzed in homogenized colon samples and results presented in Fig. 4 A-D. In particular 
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the level of MDA and CAT were significantly increased and decreased, respectively, in mice 
only treated with AOM and/or DSS (group 2).(Figure 4A-B). Our data showed that mice treated 
with crocin or its combination with 5-FU was able to reduce the level of MDA, while increasing 
the CAT or thiol activities, suggesting that crocin attenuates inflammatory responses by 
regulating oxidative stress in tumors. 
 
Crocin ameliorates multiplicity of severe inflammation with mucosal ulcers and high 
grade dysplastic crypts  
The H&E staining of resected tumors revealed an organized structure of tumor cells nests within 
stromal tissue. These tumors also showed the presence of Polypoid well-differentiated 
adenocarcinoma and pedunculated adenocarcinoma with invasion to muscular layer. Also AOM 
and/or DSS treatment resulted in the occurrence of veracious colorectal lesions, such as colitis 
with mucosal ulcers, dysplastic crypts, tubular adenoma, and tubular adenocarcinoma. The 
incidences and multiplicity of severe colorectal inflammation with mucosal ulcers, the 
inflammation score, and the presence of dysplasia are shown in Figure 5A-C. In particular our 
data showed that the total score of inflammation, crypt loss, pathological changes and histology 
score of mice treated with crocin were significantly reduced and improved, compared to control 
group (Fig. 5 D-J). Moreover, crocin was able to ameliorate multiplicity of severe inflammation 
with mucosal ulcers and high grade dysplastic crypts as detected by total score of inflammation, 
Crypt loss, pathological changes and histology scores (Fig. 5G-N). 
 
 
Crocin suppresses PI3K/Akt and Wnt/b-catenin pathways in colorectal cancer  
To further investigate the molecular mechanisms of anti-proliferative activity of crocin, the 
effects of this pharmacologically active component on PI3K/Akt and Wnt/b-catenin signaling 
pathways were analyzed. It has been reported that PI3K/Akt signaling pathway regulated 
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several downstream signaling pathways involved in cellular proliferation, survival and 
apoptosis(Michl & Downward, 2005). Thus, we examined the inhibitory effect of crocin on 
protein levels of PI3K, cyclin D1 and phosphorylated levels of Akt and glycogen synthase kinase 
3α/β (GSK-3α/β) by western blot method. Several studies indicated that the oncogenic PI3K/Akt 
signaling induces Wnt/b-catenin signaling by phosphorylation and inactivation of GSK-3α/β. 
GSK-3α/β is the key negative regulator of Wnt signaling pathway which is suppressed upon 
phosphorylation and then the activated pathway increases expression of its down-stream 
targets including cyclin D1. Cyclin D1 is one of the Wnt/β-catenin targets genes, mainly involved 
in regulation of the G1 to S phase in the cell cycle(Vadlakonda, Pasupuleti & Reddanna, 2013). 
Our results showed that crocin inhibited expression of PI3K and its downstream targets like 
cyclin D1 and survivin in CRC cells in a concentration-dependent manner (Fig. 6 A&C). We also 
showed that crocin suppressed phosphorylation of Akt and GSK 3α/β (Fig. 6C), suggesting that 
the anti-proliferative function of crocin is at least partially mediated by attenuating Wnt/PI3K 
signaling pathway activation in crocin-stimulated cells. 
 
Discussion 
To the best of our knowledge this is the first study evaluating the combination of crocin and 5-
FU in 2- and 3-dimensional cell culture models of CRC cells as well as in a mouse model of 
colitis-associated colon cancer. Our results showed that crocin synergistically enhanced the 
anti-proliferative activity of 5-FU in both in vitro and in vivo systems (Fig. 6B). Moreover, crocin 
had an antioxidant activity in homogenized colon samples. Moreover, our data showed that 
crocin and especially its combination therapy with 5-FU could dramatically reduce the tumor 
number and tumor size. More specifically, the tumor number was also considerably decreased 
in both distal and middle parts of the colon. Crocin also ameliorated multiplicity of severe 
inflammation with mucosal ulcers and high grade dysplastic crypts in mice colon cancer model, 
which the tumors showed the presence of Polypoid well-differentiated adenocarcinoma and 
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pedunculated adenocarcinoma with invasion to muscular layer. To further support the protective 
effect of crocin on colon cancer pathology, we showed that crocin improved colon length, 
disease activity index (DAI) score, as well as tumor number/colon size ratio. Taken together, our 
results not only support the importance of crocin as an alternative or adjuvant compound in 
cancer therapy (Zhang, Wang, Wen, Shoyama & Yuan, 2013), but also are in harmony with the 
assumption that crocin could improve the 5-FU chemosensitivity. 
Consistent with our findings, there are studies showing that the over-activation of the oncogenic 
PI3K/Akt and Wnt pathways play important roles in cell proliferation, differentiation and 
migration in CRC (Rahmani, Avan, Hashemy & Hassanian, 2018)(Bahrami et al., 2017b; Jason 
& Cui, 2016; Song, Li, Liu & Zhao, 2015). Chikazawa et al. reported that silencing of β-catenin, 
component of Wnt signaling, in CRC cells leads to an elevation in their sensitiveness to 
paclitaxel and irinotecan (Chikazawa et al., 2010). In agreement with this study, blocking Wnt 
activity can be considered as a strategy in order to reverse the drug-sensitivity of CD133-
positive cells to 5-FU (Deng et al., 2010). In line with this, overexpression of cyclin D1 is well-
documented in CRC (Wangefjord, Manjer, Gaber, Nodin, Eberhard & Jirstrom, 2011). In a study 
on N-nitroso-N-methylurea-induced breast cancer in rats, crocin induced cell cycle arrest via 
suppression of cyclin D1 (Ashrafi, Bathaie, Abroun & Azizian, 2015). Zhao et al. have also 
reported the potential activity of crocin in the down-regulation of cyclin D1 in bladder cancer 
(Zhao, Luo, Wu, Hu, Lv & Ji, 2008). Consistent with these findings, we showed that crocin 
suppressed cyclin D1 expression in CRC. Thus it can be hypothesized that crocin could 
increase CRC cells sensitivity to 5-FU via triggering PI3K/Akt and Wnt pathway, as evidenced 
by down-regulation of p-Akt, p-GSK3α/β, PI3K and cyclin D1. 
Inflammation regulates development of colon carcinogenesis (Campanholo et al., 2015). It has 
been evidenced that the risk of developing inflammatory bowel disease-associated CRC is 
highly correlated with the extension and duration of inflammation (Eaden, Abrams & Mayberry, 
2001). There are studies supporting the anti-inflammatory activity of crocin (Kawabata, Tung, 
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Shoyama, Sugie, Mori & Tanaka, 2012). To further investigate the anti-inflammatory effect of 
crocin, the antioxidant activity of crocin in CRC was analyzed by assessing MDA, CAT and total 
thiol levels in tissue homogenate samples. Results showed that DSS administration led to a 
remarkable elevation and reduction in MDA content and CAT activity, respectively. Although the 
total thiol concentration did not alter significantly in azoxymethane-induced colon cancer rats as 
compared with control group, but considerable alteration in MDA and CAT levels highlights the 
involvement of oxidative stress in CRC. Interestingly, crocin and 5-FU combined treatment of 
azoxymethane-induced colon cancer rats notably recovered the increased levels of MDA and 
decreased activity of CAT, as well as the decline in total thiol concentration. These data are 
compatible with the observations of other investigators using saffron and its constituents in 
order to improve oxidative damage in injury and ischemia in rats (Hosseinzadeh & Younesi, 
2002). Increasing evidence showed that oxidative stress plays crucial roles in development and 
progression of CRC (Babbs, 1990). In particular Chang et al. found that oxidative stress level 
was increased in CRC subjects (Chang, Wang, Zhao & Pan, 2008). Similarly, several studies 
have reported that lipid peroxide levels, as an indicator of oxidative stress, are higher in 
malignant colorectal tissues compared to normal tissue (Ozdemirler Erata, Kanbagli, Durlanik, 
Bulut, Toker & Uysal, 2005; Ozdemirler, Pabuccuoglu, Bulut, Bugra, Uysal & Toker, 1998). 
Accordingly, as our result showed that crocin may play an important role in CRC prevention and 
also therapy by increasing antioxidant levels while decreasing oxidants. These findings suggest 
that anti-inflammatory responses of crocin plays important role in the chemopreventive functions 
of crocin in colorectal cancer. 
In summary, our results support that crocin may potentiate the therapeutic efﬁcacy of 5-FU in 
CRC therapy via attenuating cancer cell proliferation and inflammation. These findings, not only 
suggest that crocin can be considered as a potential anti-cancer compound for CRC treatment, 
but also could sensitize cancer cells to 5-FU which is at the forefront of drugs in CRC clinical 
therapy. Although both our in-vitro and in-vivo investigations successfully brought us to this 
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conclusion but still further pre-clinical investigations are warranted to explore this therapeutic 
combination as well as its detailed antitumor mechanisms. 
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Figures legends 
Figure 1. Crocin inhibits cell proliferation and invasion of colon cancer cells. (A) Growth 
inhibitory effects of crocin (µM) after 72 hours exposure to crocin in CT-26 cells. (B) Mean 
combination index (CI) of the crocin/5-FU treatment. CI values at fractional effect analysis (FA) 
of 0.5, 0.75 and 0.9 were averaged for each experiment, and this value was used to calculate 
the mean between experiments. (C) Effect of crocin on the CRC spheroids (D) Results of 
invasion experiment in the CRC cells exposed to crocin at IC50 values for 24 hours. (E) 
Modulation of E-cadherin, MMP-2 and MMP-9 mRNA levels in CRC cells after 24 hours 
exposure to crocin (3 mM) as determined by q-RT-PCR. (F) The inhibitory effect of crocin on the 
migration of CT-26 cells. Columns or Points, mean values obtained from three independent 
experiments; bars, SEM. *Significantly different from controls. 
 
Figure 2. Cell cycle distribution of the colon cancer cells upon crocin treatment.  
CT-26 cells were treated with two concentrations of crocin (3 mM and 5 mM) for 24 hr and after 
staining with propidium iodide (PI), analyzed by flow cytometry for cell cycle and sub G1 
analysis (A-D, respectively). 
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 Figure 3. Crocin suppresses tumor growth in a mouse model of colitis-associated 
colorectal cancer. (A) The treatment schedules and development of colitis-associated 
colorectal cancer models. Mice were given 10 mg/kg body weight AOM. One week after AOM 
injection, they received 1.5% DSS/oral-gavage for 7 days, followed by 2 weeks rest. One week 
after DSS exposure groups 3, 4, and 5 were treated with crocin, 5-FU, crocin + 5-FU for 15 
weeks, respectively; (B) Colitis-associated colorectal cancer mice were treated with different 
reagents as indicated and number of tumors were analyzed in each group., (C) The same as B, 
except that tumor size was analyzed. (D) The same as B, except that tumor location was 
analyzed in each group. (E) Colitis-associated colorectal cancer mice were treated as explained 
in B and tumor area was analyzed. (F) The same as B, except that colon length was analyzed. 
(G) Picture of colons, indicating tumors in 4 groups, AOM/DSS, 5-FU, crocin and 5-FU+crocin. 
Columns or Points, mean values obtained from three independent experiments; bars, SEM. 
*Significantly different from controls. 
 
 
Figure 4. Crocin regulates oxidative stress in homogenized colon samples. Mice were 
treated ad indicated and following collection of colon samples. MDA (A), catalase (B), total 
thiol concentration (C) and SOD activity (D) were measured in colon tissues. Columns or Points, 
mean values obtained from three independent experiments; bars, SEM. *Significantly different 
from controls.  
 
Figure 5.  Crocin ameliorates multiplicity of severe inflammation with mucosal ulcers and 
high grade dysplastic crypts. A and a) tissue from group 1 (mice without AZO/DSS 
treatment); B-C, b-c) tissue from group 2 (mice with AZO/DSS treatment), Polypoid well-
differentiated adenocarcinoma (black arrows) and pedunculated adenocarcinoma (red arrows) 
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with invasion to muscular layer (white arrow); In situ adenocarcinoma (black arrows)  and 
tubular adenoma/adenocarcinoma (red arrows); D-F, d-f) effect of crocin, 5-FU and crocin+5-FU 
on colon; G) total inflammation score; H) Crypt loss score; I) Pathological changes score; J) 
Histology score; Columns or Points, mean values obtained from three independent experiments; 
bars, SEM. *Significantly different from controls. K-N) a representative picture of inflammation 
with respect to effect of crocin, 5-FU and crocin+5-FU. The H&E stained histopathological 
examination illustrated that there were no pathological changes in ventricular muscle structure 
in the control group (A,a). In contrast, in LPS group, increased infiltration of inflammatory cells 
and disarrangement of myofibers were observed (B-C, b-c). Administration of corcin and its 
combination with 5-FU illustrated improvement of pathological changes).  
 
Figure 6. Schematic representation of the molecular mechanisms involved in the 
synergistic effects of crocin on 5-FU. A-B) Modulation of CyclinD1 and surviving at mRNA 
levels and PI3K, Cyclin D1, P-Akt and p-GSK3ɑ/β at protein level in CRC cells after 24 hours 
exposure to crocin (3 mM) as determined by q-RT-PCR and Western blot. Columns mean 
values obtained from three independent experiments; bars, SEM. *Significantly different from 
controls.C) Crocin inhibits PI3K/Akt and Wnt activation and enhances the growth inhibitory 
effects of 5-FU through its pronounced anti-proliferative and anti-invasive effects, as well as the 
attenuation of inflammation and oxidative stress status. 
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